NCT05646758 - A Clinical Trial of TQB2934 for Injection in Multiple Myeloma Subjects | Biotech Hunter

Enrollment

140

Participants

Timeline

Start Date

March 17, 2023

Primary Completion Date

October 31, 2024

Study Completion Date

October 31, 2025

Conditions

Multiple Myeloma

Interventions

DRUG

TQB2934 injection

TQB2934 is an anti-CD3×BCMA double-specific antibody，which at one end binds to the CD3 receptor on the surface of T cells ,and the other end binds to BCMA to recruit T cells around BCMA-positive cells, which can activate T cells .Active T cells release granzyme and perforin to kill BCMA-positive target cells.

Trial Locations (7)

100032

RECRUITING

Peking Union Medical College Hospital, Beijing

200032

RECRUITING

Zhongshan Hospital of Fudan University, Shanghai

215000

RECRUITING

The Second Affiliated Hospital of Soochow University, Suzhou

250117

RECRUITING

Shandong First Medical University Affiliated Tumor Hospital, Jinan

325000

RECRUITING

The First Affiliated Hospital of Wenzhou Medical University, Wenzhou

450008

RECRUITING

The Henan Cancer Hospital, Zhengzhou

510060

RECRUITING

Sun Yat-Sen University Cancer Canter, Guangzhou